Report
Cure introduces Innovation Index, Ranking Institutions That Turn Discovery Into Medicine
Overview
Cure, the life sciences innovation campus headquartered in New York City, has launched the Cure Innovation Index — the first national ranking of U.S. biomedical research institutions built specifically around translational performance, meaning the ability to move discoveries out of the lab and into therapies that reach patients.The Index evaluates 303 institutions (drawn from a starting pool of more than 6,000) across two categories — Universities, and Institutes & Centers — and scores each on three domains: entrepreneurial readiness, research capabilities, and market translation. The methodology pulls from more than a dozen federal and commercial databases, an original audit of every institution, and surveys of more than 3,000 scientists, industry leaders, and biomedical experts.
The Big Picture
New York ranks #2 nationally among states for ranked institutions, with 27 total — 20 universities and 7 institutes/centers.
New York has the most ranked universities of any major life-sciences state, with the Icahn School of Medicine at Mount Sinai, Cornell, and Columbia all placing in the top 20 universities nationally.
On the institute side, Memorial Sloan Kettering Cancer Center leads New York’s institute list and sits in the national top 5 for Institutes and Centers.
These rankings combined with Cure’s initiative demonstrate that New York is one of the densest concentrations of translational biomedical talent in the country, and where the national scoreboard for that work is being built. As federal NIH support contracts and private capital becomes the decisive factor in which science survives, New York’s combination of ranked institutional depth plus Cure’s NYC-based diagnostic platform positions the city as a critical convening point for the next era of U.S. biomedical commercialization.
